Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
about
Effect of statin therapy on the progression of coronary atherosclerosis.Resistance exercise and lipoproteins in postmenopausal women.Current Perspectives on rosuvastatin.Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients?Rosuvastatin inhibits high glucose-stimulated upregulation of VCAM-1 via the MAPK-signalling pathway in endothelial cells.
P2860
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
@en
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
@nl
type
label
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
@en
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
@nl
prefLabel
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
@en
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
@nl
P2860
P1433
P1476
Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
@en
P2093
Gianna Fabbri
P2860
P2888
P304
P356
10.1007/S12325-009-0025-6
P407
P577
2009-05-14T00:00:00Z